R-Pharm US has acquired Ixempra (ixabepilone) from Bristol-Myers Squibb. Ixempra received marketing approval from the U.S. Food and Drug Administration (FDA) in 2007 and in 18 other markets globally. Ixempra is indicated as monotherapy or in combination with capecitabine for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine. With the acquisition, R-Pharm US has launched its U.S. commerci...